Search 

We at Singh Biotechnology (SBT) are interested in meeting with you to exploring possible opportunities for partnering/in-licensing/scientific collaboration.

SBT is a start-up biotech company established in 2014. We discover/develop unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune, ophthalmological, and viral diseases by leveraging our propriety novel technology platform. Using this technology platform SBT has been able to generate therapeutic sdAbs that specifically target intracellular molecules of interest that play an important role in the pathogenesis of disease(s). Our lead therapeutic (SBT-100) is a bi-specific sdAbs that specifically targets and inhibits intracellular KRAS and signal transducer and activator of transcription 3 (STAT3) proteins.

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.

Approximately 900,000 people annually in the United States suffer from damage to the articular cartilage and subchondral bone, with the knee being the most commonly affected. Articular cartilage lesions have a limited intrinsic ability to heal and often result in osteoarthritis (OA). Progression to OA poses significant economic burden for the United States, totaling over $300 billion annually, and negatively impacting 54.4 million adults (23% of the population). Current strategies for cartilage restoration include bone marrow stimulation (microfracture) and autologous chondrocyte implantation (ACI). These methods have high failure rates (25-50% at 10 years), prolonged rehabilitation times (> 12 months), and show decreasing efficacy in patients older than 40-50 years of age. 

Sparta Biomedical is developing the first-of-its kind osteochondral repair technology (SBM-01) for support the restoration of the cartilage-bone unit. This purpose-built technology is comprised of a novel biomimetic material possesses cartilage-like properties-- tension, compression, tribology, and fatigue.  The patent-pending surface is combined with a uniquely designed base to promote efficient osseous attachment and stable fixation over the long-term. Sparta’s technology will be a significant advancement in the current surgical standard of care. It will result in substantial pain reduction, immediate weight bearing post-operatively, and full range ambulation.

Sparta has assembled a nationally recognized team of scientists, clinicians, orthopedic regulatory experts to develop SBM-01 rapidly and cost effectively. SBM-01's risk profile enables an efficient regulatory path. Furthermore, it is well positioned to obtain Breakthrough Device Designation from the US FDA.

Summary / Data Stingray Therapeutics: Novel Innate Immunity Target - Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (ENPP1). Stingray Therapeutics, a biotechnology company located in the Texas Medical Center (TMC), is developing next-generation innate immune modulators targeting the STING (Stimulator of Interferon Genes) pathway. Clinical Candidate (SR-8541A) - Potent and Selective Inhibitor of ENPP1 SR-8541A Binds the Catalytic Pocket of ENPP1ENPP1 Inhibitors Activate the STING pathway and Promote Lympocyte Infiltration of Breast Cancer Single-Agent Activity (CT26 - Colon), 57.8% Decrease in Tumor Volume SR-8541A Treatment and Radiation Theapy Demonstrate Synergy and Abscopal Anti-Tumor Response in MC38 Mode Description - STING / ENPP1 The STING pathway is the body’s first level of defense against foreign pathogens (bacteria / viruses) and critical for enabling the adaptive immune system (e.g. T-Cells) to recognize cancer cells and attack. SR-8541A blocks ENPP1’s activity which cancer upregulates to suppress the STING ST imulator of IN terferon G pathway both in cancer cells and in the surrounding tumor microenvironment (TME). By downregulating ENPP1, SR-8541A enhances the innate immune response where adaptive immunity (e.g. checkpoint inhibitors) cannot defeat the cancer alone.SR-8541A used in combination with checkpoint inhibitors enables both arms of the immune system (innate / adaptive) to fight cancer providing a dramatic leap forward in immune-oncology treatment in tumors unresponsive to checkpoint inhibition (prostate , colorectal) and aiding response in tumors where checkpoint inhibitors are currently used melanoma, head and neck, triple-negative breast). Other advantages of ENPP1 inhibition include blocking adenosine production, an important immune suppressor, and helping to block cancer’s ability to repair DNA following targeted and / or chemotherapy. While Stingray's primary focus is oncology, it is also known that activation of the STING pathway via ENPP1 inhibition could have a major impact in infectious diseases, including Mycobacterium Tuberculosis and Hepatitis B, through the stimulation of host defense immunity. Timeline: Pre-IND Enabling Studies: 3Q2020 - 1Q2020 GLP Toxicology Single-Agent Pre-Clinical Studies (interferon responsive tumors - CTCL, Myelofibrosis and immune responsive tumors) Combination Studies - checkpoint inhibitors, anti-CD38 in multiple myeloma, PRRT (liquid radiation), PARP inhibitors, chemotherapy, CAR-T / CAR-NK cells File IND - 1Q2020 Financing: Stingray is raising $1.5M of bridge financing (convertible note funding pre-IND studies) leading to a $15M Series A advancing the company’s lead small molecule compound, SR-8541A, through Phase 1 clinical studies. Use of Proceeds $1M: Pre-Clinical (Chemistry, Biology, CMC, Toxicology) $1M: IP, Legal $11M: Two (2) Phase 1 Clinical Studies $2M: Administration

Dear Prospect Customer:

I would like to introduce my company (TDM Pharmaceutical Research, Inc) to you. TDM Pharmaceutical Research, INC, is a highly productive, intensely focused, quality-oriented CRO; we are experienced, well established, and driven by scientific merit. As a full-service GLP and GCP compliant laboratory, TDM offers a variety of discovery, research, development, bioanalytical, and consulting services to support discovery and development of pharmaceutical and chemical products. We pride ourselves on prompt data turnaround and addressing our clients’ needs with the accuracy and quality that are critical to their businesses.

TDM is uniquely different from other CROs: our over 90 years of combined industry experience allows us to resolve complex issues by providing comprehensive solutions in pharmacokinetics, toxicokinetics, pharmacokinetic/pharmacodynamic correlations, and more.

We are experienced in both the sponsor and the CRO position, so we anticipate and address the needs of our clients. Resourceful, committed personnel provide proactive support throughout each project, and respond to potential issues immediately.

Our myriad clients include both companies and individuals in the pharmaceutical and related industries. By selecting TDM as the partner for your next project, you will find we take each job and its needs personally; our focus is always on the client!

If you have any question, please feel free to contact me at: changfu.cheng@tdmrxresearch.com, or phone at 1-774-258-2425.

Thanks!

Changfu Cheng, PhD

President

TDM Pharmaceutical Research, Inc

https://tdmpharmalab.com